WO2001070251A1 - Composition antineoplasique - Google Patents
Composition antineoplasique Download PDFInfo
- Publication number
- WO2001070251A1 WO2001070251A1 PCT/JP2001/002315 JP0102315W WO0170251A1 WO 2001070251 A1 WO2001070251 A1 WO 2001070251A1 JP 0102315 W JP0102315 W JP 0102315W WO 0170251 A1 WO0170251 A1 WO 0170251A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- production
- composition
- cancer
- main component
- product obtained
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- 230000001093 anti-cancer Effects 0.000 title abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 60
- 230000001939 inductive effect Effects 0.000 claims abstract description 33
- 238000012258 culturing Methods 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 9
- 108010065805 Interleukin-12 Proteins 0.000 claims abstract description 8
- 102000013462 Interleukin-12 Human genes 0.000 claims abstract description 8
- 229940117681 interleukin-12 Drugs 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 151
- 201000011510 cancer Diseases 0.000 claims description 95
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 52
- 239000000047 product Substances 0.000 claims description 45
- 230000019734 interleukin-12 production Effects 0.000 claims description 44
- 230000037406 food intake Effects 0.000 claims description 37
- 230000028993 immune response Effects 0.000 claims description 18
- 230000037396 body weight Effects 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 150000001720 carbohydrates Chemical class 0.000 claims description 12
- 241000233866 Fungi Species 0.000 claims description 11
- 235000015872 dietary supplement Nutrition 0.000 claims description 8
- 239000002075 main ingredient Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 238000009630 liquid culture Methods 0.000 claims description 5
- 102000000589 Interleukin-1 Human genes 0.000 claims description 3
- 108010002352 Interleukin-1 Proteins 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 4
- 241000401653 Ganoderma orbiforme Species 0.000 abstract 1
- 230000000153 supplemental effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 42
- 239000000126 substance Substances 0.000 description 20
- 239000000523 sample Substances 0.000 description 19
- 210000000581 natural killer T-cell Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 241000282412 Homo Species 0.000 description 12
- 108091007602 SLC58A1 Proteins 0.000 description 11
- 230000002538 fungal effect Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 7
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 229920000855 Fucoidan Polymers 0.000 description 5
- 230000029662 T-helper 1 type immune response Effects 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000000411 inducer Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004241 Th2 cell Anatomy 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000000439 tumor marker Substances 0.000 description 4
- 230000005760 tumorsuppression Effects 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 241000512259 Ascophyllum nodosum Species 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
- 206010027452 Metastases to bone Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 3
- 206010046392 Ureteric cancer Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- -1 oligosaccharide sulfate Chemical class 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000008732 thymoma Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 150000008267 fucoses Chemical class 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000019736 interleukin-11 production Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000029069 type 2 immune response Effects 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- QIGJYVCQYDKYDW-UHFFFAOYSA-N 3-O-alpha-D-mannopyranosyl-D-mannopyranose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(CO)OC(O)C1O QIGJYVCQYDKYDW-UHFFFAOYSA-N 0.000 description 1
- 101710190981 50S ribosomal protein L6 Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 108010004141 HLA-B35 Antigen Proteins 0.000 description 1
- 108010075326 HLA-B51 Antigen Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000688214 Mus musculus Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 101000868281 Mus musculus Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000616015 Mus musculus Magnesium transporter protein 1 Proteins 0.000 description 1
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 1
- 108010001882 NK Cell Lectin-Like Receptor Subfamily B Proteins 0.000 description 1
- 102000000835 NK Cell Lectin-Like Receptor Subfamily B Human genes 0.000 description 1
- 108091008877 NK cell receptors Proteins 0.000 description 1
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 101150008223 SLX1 gene Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000037842 advanced-stage tumor Diseases 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000003961 cecum cancer Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000011902 cervical lymphadenopathy Diseases 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- QIGJYVCQYDKYDW-NSYYTRPSSA-N nigerose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-NSYYTRPSSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229940054870 urso Drugs 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a composition, an orally ingestible composition focused on inducing the production of interleukin 12 (IL-12), or a composition ingested in anticipation of an anticancer effect by focusing on the induction of IL-11 production.
- IL-12 interleukin 12
- cancer malignant neoplasms
- cancer malignant neoplasms
- Immunostimulants were found to be useful for treating cancer, but all of the compounds obtained as immunostimulants had weak anticancer effects, and immunotherapy alone or chemotherapy Sufficient therapeutic effects on cancer have not been achieved even with the combination treatment with.
- Dr. Yagida first focused on the usefulness of a substance that induces IL-12 in vivo as a technological method in cancer treatment. I found that it has that function.
- IL-12 has been known to have an anticancer effect, but there is a fact that if IL-12 itself is directly administered to a living body, patients will not be able to tolerate treatment due to side effects.
- IL-12 itself could not be used as an anticancer drug.
- the formulation containing AHCC reported by Yagita achieved a remarkable cure / life extension effect in the treatment of cancer. That is, Yagida achieved the purpose of treating cancer by administering an effective amount of AHCC capable of inducing IL_12 in vivo (Japanese Patent Application Laid-Open No. 10-139670).
- IL-12 is a natural killer (NK) cell and LAK cell (Ly cell) that enhance the production of interferona (IFNa), mpi ki ne ac ti va tedkillercell), and killer T cells.
- IFNa is a cytokine that induces the body's immune response to a state where T helper 1 cells (Thl) act.
- the state in which Th1 acts is a state in which natural killer T (NKT) cells and killer T cells are likely to exert their effects, that is, a state in which IL-12 and IL-12 are produced in large amounts.
- Killer T cells and LAK cells are known as cells involved in cancer immunity.
- NK cells are also involved in the anticancer activity of living organisms.However, NK cells do not correlate with clinical pile cancer effects and their activities. It has been proved by Yagida that NK activity is completely inversely correlated, and it is concluded that NK cells are not involved in the anticancer activity in humans.
- Yagida has established that a substance capable of inducing the production of IL-12 may be a promising anticancer substance, and the present invention has confirmed this.
- the present inventor believes that advanced cancer or terminal cancer or T helper 2 cell (Th2) -based immune response, which has a novel IL-12 production-inducing ability different from the IL-12-inducing effect exhibited by AHCC, is mainly The present inventors have found a composition derived from mushroom mycelium that is effective for a functioning cancer patient and completed the present invention.
- Th2 T helper 2 cell
- one embodiment of the present invention is a composition for inducing the production of IL_12, which comprises, as a main component, a mycelial fraction of a product obtained by cultivating a mycelium of Shimane perennial fungus. is there.
- One embodiment of the present invention is a composition for inducing the production of IL-12, comprising, as a main component, a mycelial fraction of a product obtained by liquid culturing of Shima perennial fungal hypha.
- One embodiment of the present invention is a composition for oral ingestion, which induces the production of IL-112, which contains, as a main component, a mycelium fraction of a product obtained by cultivating a mycelium of Shimane perennial fungus.
- One embodiment of the present invention is a composition for oral ingestion which induces the production of IL-12, comprising, as a main component, a mycelium fraction of a product obtained by liquid culturing of Shima perennial fungal hypha.
- One embodiment of the present invention is characterized in that a main ingredient is orally ingested from 100 mg to 2,000 mg / kg body weight / day as an amount of the substance that exerts the ability to induce IL-12 production in a living body.
- An orally ingestible composition for inducing the production of IL-12 comprising, as a main component, a mycelial fraction of a product obtained by cultivating a mycelium of Shimane perennial fungus.
- One embodiment of the present invention is characterized in that the main ingredient is orally ingested at a dose of 100 mg to 2,000 mg / kg body weight / day as the amount of intake that exhibits the ability to induce IL-112 production in a living body.
- composition for inducing IL-12 production which contains, as a main component, a mycelium fraction of a product obtained by liquid cultivation of a perennial mushroom mycelium.
- One embodiment of the present invention is characterized in that it is useful for patients with advanced cancer or terminal cancer, and has a mycelial fraction of a product obtained by culturing a mycelium of Shima perennial mushroom as a main component.
- One embodiment of the present invention is characterized by being useful for patients with advanced cancer or terminal cancer, and comprising, as a main component, a mycelial fraction of a product obtained by liquid culturing of Shima perennial mushroom mycelium.
- a composition for inducing the production of IL-12 is characterized by being useful for patients with advanced cancer or terminal cancer, and comprising, as a main component, a mycelial fraction of a product obtained by liquid culturing of Shima perennial mushroom mycelium.
- One embodiment of the present invention is characterized in that it is useful for patients with advanced cancer or terminal cancer, and has a mycelial fraction of a product obtained by culturing a mycelium of Shima perennial mushroom as a main component.
- One embodiment of the present invention is useful for patients with advanced cancer or terminal cancer.
- An orally ingestible composition for inducing the production of IL-12 comprising, as a main component, a mycelial fraction of a product obtained by liquid culturing of Shima perennial fungal mycelium.
- One embodiment of the present invention relates to an oral intake of 100 mg to 2,000 mg / kg: body weight / day of a main component as an intake that exhibits the ability to induce IL-12 production in a living body. It is useful for patients with advanced or terminal cancer, and is characterized by its ability to produce IL-12, containing as its main component the mycelial fraction of the product obtained by culturing the mycelium of Shima perennial mushrooms. It is a composition for oral ingestion that induces.
- One embodiment of the present invention is characterized in that a main ingredient is orally ingested at a dose of 100 mg to 2,000 mg / kg body weight / day as an amount for exhibiting the ability to induce IL-12 production in a living body. It is useful for patients with advanced cancer or terminal stage cancer, and contains the mycelial fraction of the product obtained by liquid culturing of Shima perennial mushroom mycelium as a main component. It is a composition for oral ingestion that induces.
- One embodiment of the present invention relates to a mycelium of a product obtained by culturing a mycelium of Shimane perennial mushrooms, which is useful for a cancer patient whose Th2 cell-based immune response mainly functions.
- One embodiment of the present invention is directed to a mycelium of a product obtained by liquid culturing a mycelium of Shimane perennial mushrooms, which is useful for a cancer patient whose Th2 cell-based immune response is mainly functioning.
- One embodiment of the present invention relates to a mycelium of a product obtained by culturing a mycelium of Shimane perennial mushrooms, which is useful for a cancer patient whose Th2 cell-based immune response mainly functions.
- One aspect of the present invention is a product obtained by liquid culturing Shima perennial mushroom mycelia, which is useful for a cancer patient whose Th2 cell-based immune response is mainly functioning. It is a composition for oral ingestion which induces the production of IL-112, comprising a mycelium fraction of the present invention as a main component.
- One embodiment of the present invention is characterized in that a main ingredient is orally ingested from 100 mg to 2,000 Omg / Kg body weight / day as an ingestion amount that exhibits the ability to induce IL-12 production in a living body.
- Production of IL-12 which is useful for cancer patients whose two-cell immune response is mainly functioning and contains as a main component the mycelial fraction of the product obtained by culturing Shima perennial fungal hyphae Is a composition for oral ingestion that induces
- One embodiment of the present invention is characterized in that a main ingredient is orally ingested from 100 mg to 2,000 Omg / Kg body weight / day as a dose that exhibits the ability to induce IL-112 production in a living body.
- Production of IL-12 which is useful for cancer patients whose cell-based immune response is mainly functioning and contains as a main component the mycelial fraction of the product obtained by liquid culture of Shimane perennial fungal mycelium Is a composition for oral ingestion that induces
- One embodiment of the present invention is any of the above-mentioned compositions, which is used in combination with a composition containing a saccharide having a 1 ⁇ 3 steric structure as a main component.
- One embodiment of the present invention is any of the above-mentioned compositions for oral ingestion, which is used in combination with a composition containing a saccharide having a 1 ⁇ 3 steric structure as a main component.
- One embodiment of the present invention is the composition for oral intake according to any of the above, which is a dietary supplement preparation for oral intake.
- One embodiment of the present invention is a commercial medium carrying the above-described contents of the present invention.
- One embodiment of the present invention is a commercial method using the above-described contents of the present invention. Description of the drawings
- FIG. 1 shows the protocol of the experiment.
- FIG. 2 is a graph showing serum IL-12 (pg / ml) of tumor-bearing mice.
- the present inventor has reported that, in addition to a substance that induces IL-12 production particularly effectively in early stage cancer patients, such as AHCC, the Shima perennial mushroom according to the present invention is used as an IL-12 production inducer.
- AHCC mainly induces IL-112 production in cancer patients and mice in which the Th1 immune response is functioning.
- cancer patients and mice in which the Th1 immune response is functioning are: (A) at the gene level, (1) mice that produce TNF and IFNNIL-12.
- congenic mice refer to BIO mice or B10A mice, and (2) humans tend to produce TNF, IFN ⁇ and IL-11, specifically humans.
- TNF shed in mice, pointing peg mice produce I Fny and IL- 12, for example Konjienikku.
- Mouse (congenic mouse) in Balb / c mice or B10d 2 mice (2) human In humans, TNF, humans that are not likely to produce IFNa or IL_12, specifically humans that have human leukocyte antigen types such as HLA-B35, B7, and B39.
- IAP is 600 / g / m1 or more
- IL-10 is 600 pgZm1. Refers to the above cancer patients.
- One embodiment of the present invention is to administer a composition focused on inducing the production of inleukin-12 (IL-12), particularly an IL-12 production inducer consisting of a known mushroom component such as AHCC (Aminoup Co., Ltd.).
- IL-12 inleukin-12
- an IL-12 production inducer consisting of a known mushroom component such as AHCC (Aminoup Co., Ltd.).
- AHCC Aminoup Co., Ltd.
- the above composition can be a composition for oral ingestion characterized by being orally ingested.
- one embodiment of the present invention relates to a dietary supplement for oral ingestion that is taken in expectation of a stake cancer effect using the ability to induce the production of insulin-leukin 12 (IL-12) as an index.
- IL-12 insulin-leukin 12
- It contains a substance capable of inducing IL-12 production that can be applied to patients with insufficient IL-12 production even when administered with an IL-12 production inducer consisting of a known mushroom component such as company amino up.
- the composition of the present invention may be used for lung cancer (lung squamous cell carcinoma, lung adenocarcinoma, small cell lung cancer), thymoma, thyroid cancer, prostate cancer, kidney cancer, bladder Cancer, colon cancer, rectal cancer, esophageal cancer, cecum cancer, ureteral cancer, breast cancer, cervical cancer, brain tumor, tongue cancer, pharyngeal cancer, nasal cancer, laryngeal cancer, stomach cancer, liver cancer, bile duct cancer, testicular cancer, ovary It is effective for the treatment of cancer, endometrial cancer, metastatic bone cancer, malignant melanoma, osteosarcoma, malignant lymphoma, plasmacytoma, liposarcoma, etc., but is not limited to these cancers.
- administration of IL-12 production inducers such as AHCC (Amino Inc.)
- AHCC Amino Inc.
- the amount of induced IL-112 was determined to be sufficient to induce the amount of IL-112 in serum, and the enzyme was directly measured without indirect measurement as in humans. It can be measured with an immunoassay (ELISA) measurement kit.
- ELISA immunoassay
- the substance capable of inducing IL-12 production can be assayed by continuously ingesting the substance capable of inducing IL-12 production orally and subsequently increasing the amount of IL-12 in the blood.
- the amount of IL-12 in the blood cannot be measured directly due to the presence of the inhibitor in the blood.
- the measurement of the amount of IL-12 induced in a cancer patient cannot be performed in the blood of the cancer patient.
- a peripheral blood mononuclear cell fraction isolated from and prepared from a stimulant is cultured after centrifugation, followed by centrifugation to remove cells. Separation of the mononuclear cell fraction from blood may be performed by a known method.For example, it is possible to simply carry out a specific gravity centrifugation method using a Ficoll-Control solution or the like to separate cells used for c culture.
- the number is 0.5 ⁇ 10 6 / m 1 to 1 ⁇ 10 7 / m 1, preferably 1 ⁇ 10 6 / ml.
- PHA magglutinin
- a substance that stimulates cells magglutinin (PHA)
- PHA magglutinin
- the substance that stimulates cells is not limited to PHA, and any substance capable of stimulating cells to produce an immunophysiologically active substance may be used to achieve the object of the present invention.
- phorbol 12- Myristate- 13- Acetate PMA + I o nomy cin N LP S (L ipopol ys ac char ide, PWM (Poke Weed Mitogen) , etc. can be mentioned, et al are.
- the amount of IL-12 produced by the stimulation of the mononuclear cell fraction is 7. It means a function that enhances to 8 pg / ml or more, or a function that enhances the amount of IL-112 produced before administration of a certain substance.
- composition according to one embodiment of the present invention contains, as an active ingredient having an ability to induce IL-112 production, a mycelium fraction of Shimane perennial mushroom.
- composition according to one embodiment of the present invention which contains the mycelium fraction of Shima perennial mushroom as an active ingredient that induces IL-12 production, comprises IL-1 at each stage of cancer progression.
- composition of the present invention containing the Shima perennial mycelium fraction as an active ingredient exhibits a sufficient IL-12 production-inducing ability even in the early stage of cancer, and is characteristically the same in advanced terminal cancer. It exerts an equal or stronger ability to induce IL-12 production.
- AHCC exerts a characteristic ability to induce IL-12 production in the early stage of cancer, but its ability to induce declines as the cancer progresses.
- composition containing the Shima perennial fungal mycelium fraction as an active ingredient that induces IL-12 production which is one embodiment of the present invention, has an immunological response mainly functioning in vivo and has a T-like response. Inducing IL-112 production even in cancer patients with an h2-based immune response is a major difference from known AHCC.
- the dose of the composition according to the present invention is 1 to 2,000 mg / Kg body weight per day, more preferably about 100 to 2,000 mg / Kg body weight per day.
- the period is about 10 days to about 1 year, and the frequency of administration is 1 to several tens / month, preferably by oral ingestion.
- parenteral ingestion including subcutaneous, intramuscular, intravenous, intradermal etc. injection) is also possible by reducing the dosage and preparing the compound to a parenterally acceptable quality.
- the Shima perennial fungal mycelium fraction according to the present invention is known as a food material.
- the mycelium fraction of the Shimane perennial fungus is produced by culturing the hyphae obtained by culturing the cultured mother bacterium of the Shimane perennial mushroom, for example, by liquid culture in a medium containing an appropriate nutrient source, and then producing it. Further, the mycelium is fractionated from the culture solution, and the mycelium is extracted with a solvent, preferably with hot water. The obtained extract is sterilized with a membrane filter, and the filtrate is concentrated to produce a dried powder.
- mycelial fraction of the product obtained by culturing the mycelium of Shimane perennial mushroom are defined as the mycelial fraction of the product obtained by culturing the mycelium of Shimane perennial mushroom.
- a solid fraction obtained from a culture solution was directly washed and dried as a mycelial fraction to obtain a sample.
- Oral preparations are prepared into tablets, powders, capsules, syrups and the like. When formulating, it can be formulated using conventional means by mixing necessary additives such as excipients, disintegrants, binders, and / or lubricants. If necessary, flavoring agents, coloring agents, flavors, stabilizers, bactericides, and / or preservatives may be added.
- Parenteral preparations include antioxidants, buffers, and / or bacteriostats, and may include aqueous or non-aqueous sterile injectable solutions or suspensions or enrichments that may include solutes to make them isotonic with the blood of the patient. It is prepared as an aqueous or non-aqueous sterile suspension which may contain a thickening agent. Single or multiple doses of the formulation may be provided in containers, for example, sealed ampules and vials. Also, it may be stored in a lyophilized state that requires only the addition of a sterile liquid carrier immediately before use.
- composition for inducing the production of IL-112 which is one embodiment of the present invention, is orally administered with an effective amount of a mycelial fraction of a product obtained by culturing a mycelium of Shimane perennial mushroom. It can be a composition for oral ingestion.
- composition for oral ingestion containing an effective amount of a mycelium fraction of a product obtained by culturing the mycelia of Shimane perennial mushroom which is one embodiment of the present invention, is expected to have a pile cancer effect as a result of ingestion. It can be a dietary supplement formulation.
- composition according to the present invention the composition for oral ingestion, and the health food supplement for oral ingestion may be simply referred to as ILY.
- the above ILY further enhances the new immunotherapy for cancer (NITC) practiced by the inventor.
- the outline of the new immunotherapy practiced by the inventor, Dr. Asakuni Yagida is as follows. Its pillars are induction of IL-12, activation of NKT cells, And immunological cancer treatment with a biological response modifier (BRM preparation) using angiogenesis inhibition as a marker.
- BRM preparation biological response modifier
- angiogenesis inhibitor a shark cartilage preparation (patent No. 3105313), Bettershark MC or LO (Seishin Co., Ltd.) is used at a dosage of 20 days.
- ILX (Tozai Pharmaceutical Co., Ltd.) for patients whose Th1 immune response is mainly functioning is 3 g to 20 g / day. , Preferably at a dose of 6.0 g / day (or AH CC 6.0 g / day; currently discontinued); b) patients with a predominantly functional Th2-mediated immune response Is used at a dosage of 1 g to 20 g / day or every other day, preferably 3.0 g / day or every other day.
- a composition mainly composed of a saccharide having a 13-dimensional structure, which is a substance capable of stimulating the NK cell antigen receptor (NKR-P1) is used.
- NKT cells selectively act on NKR-P 1 (natural killer P 1) to activate NKT cells.
- NKR-P 1 natural killer P 1
- Nigerooligosaccharides saccharide substances having a 1 ⁇ 3 steric structure
- Example product Nigerooligosaccharide liquid sugar / sales Takeda Food Industry Co., Ltd./Main Nigerooligosaccharides: Nigerose HI-D-Glc P- (1-3) -D-Glc 2Nigeguchi Sylglucose Hi-D-Glc / (1 ⁇ 3) - ⁇ -D-Glc-(1 ⁇ 4) -D-Glc 3 Nigerosylmaltos HI- D-Glc /?-(13) -HI- D-Glcp- (1-4)-a -D-Glc p- (1 ⁇ 4) -D-Glc; Glc is glucose, p is an abbreviation of vir
- oligosaccharide sulfate eg, sales company Z Co., Ltd .: Shirako seaweed-derived extract
- the active ingredient is at least one selected from a galactan sulfate oligosaccharide having a 1 ⁇ 3 bond and a galactan sulfate oligosaccharide comprising a 1 ⁇ 3 bond and / or a 1 ⁇ 4 bond).
- the compound is not limited to these, and is a saccharide substance having a 13-dimensional structure (a sugar component having a 1 ⁇ 3 glucoside bond structure), and NKR-P1 (natural killer P1) of NKT cells. Substances that act selectively on NKT cells and have the ability to activate NKT cells.
- the substance capable of activating NKT cells may be a composition containing a polysaccharide having this structure and Z or 2 to 10 oligosaccharides.
- the first pillar of the new immunotherapy selects and improves shark cartilage, which is the most effective, safe, easy, and economical.
- Better Shear MC or L0 was developed.
- 20 g per day is orally administered on an empty stomach in 2-3 divided doses.
- the second pillar, IL-12 inducer is ILX (conventionally AHCC), which acts on mice or humans whose Th1 immune response is mainly functioning.
- oral administration is performed at about 3 g / day, and for advanced cancer, for example, at about 6 g / day.
- ILX is the ratio of Shiitake mushroom 2: Suehiro mushroom 2: Reishi 1 Of mycelial components formulated at a high rate, and is rationally formulated based on the difference in susceptibility of various patients with mushroom mycelium processed products in which the Th1 immune response is mainly functioning .
- ILX (lg / Kg / day) was administered, IL-12 production ability was maintained in the above-mentioned tumor-bearing mouse not only on day 7, but also on day 10 and further on day 14 .
- the resulting PSK is administered, for example, at about 3 g / day or every other day.
- the ILY according to the present invention functions as a substitute for PSK. Based on these, various natural forms of synthetic bimin and urso (300 mg or 600 mg / day) and active bimin D3 (1.0 / g / day) should be administered in combination. Also add live SPG, OK432 and BCG vaccines as needed.
- NKT cells For the third pillar, NKT cells, saccharides having a 1 ⁇ 3 steric structure, which is a prescription to stimulate NKR-P1, are applied.
- CR Complete Response
- PR Partial Response
- IL-12 was produced and was found in the same proportion as those in whom treatment was effective. Therefore, in order to examine whether NK T cells are activated by this new immunotherapy, the T cell receptor V and 24V 511 of NK T cells and the NK cell receptor NKR-P1 (CD3 X CD 16 1) was studied. The activation of NKT cells was determined by measuring the peripheral blood of a patient at a flow site every day.
- the ratio of NK T cells increases to preferably at least 10%, particularly preferably at least 16%, it is assumed that NK T cells have been activated.
- the NKR-P1 receptor activated by saccharides having a 13-dimensional structure, such as nigerosugar and oligosaccharide showed a positive correlation with the amount of IFN ⁇ IL112 produced, Activated with lipids
- the value of V 2 4 V? 1 1 showed a negative correlation. It also showed a high correlation with NKR-P1 in CR and PR cases.
- CTLs cytotoxic T cells
- another NKT cell may act as effector cells in cases where NITC is effective.
- compositions or the composition for oral ingestion containing the mycelium fraction of the perennial perennial mushroom according to the present invention is further useful for treating cancer and may be an aspect of the present invention.
- one embodiment of the present invention comprises the above-mentioned Shima perennial fungal mycelium fraction according to the present invention, which is used in combination with the above-mentioned composition containing a saccharide having a 1 ⁇ 3 tertiary structure as a main component. Supplementary food preparation for oral ingestion.
- the present invention has a composition containing the mycelial fraction of the product obtained by culturing the mycelia of Shimane perennial mushroom as an active ingredient, and mainly functions in the stage of cancer progression and in vivo.
- the composition functions mainly for advanced cancer or terminal cancer or Th2-based immune response It is an indication that it is effective for cancer patients in a state where it is present, and if these are carried in a commercial medium, it will be a means of differentiating the value of the product. Therefore, commercial media carrying such information is extremely useful.
- the above-mentioned commercial medium means printed matter such as pamphlet, booklet, or publication, magnetic recording medium such as floppy disk (FD), MO, or CD-ROM, or wide-area information transmission medium such as the Internet. I do. Moreover, the commercial use of this information is a very useful tool because it provides a means of differentiating the value of the product.
- Example 1
- the mycelium of the Shima perennial mushroom (mycelium) is liquid-cultured, and the mycelium is centrifuged from the obtained mycelium culture solution (5,000 to 10, at OOO rpm for 10 to 30 minutes) to form a solid.
- the fractions were collected, washed with water and 95% ethanol, and dried at 85 ° C overnight.
- a dry powder sample of the obtained mycelium fraction was used as a distilled water suspension and used as a specimen (hereinafter sometimes referred to as SM).
- SM specimen
- SM sample
- LLC Lewis Lung Carcinoma
- a C57 / BL10 SLC mouse (B10 mouse) purchased from SLC, Inc. was used.
- the study consisted of four groups: a non-tumor-bearing group and a normal mouse group as a control group, in addition to the SM- and AHCC-administered groups for the tumor-bearing mice.
- the tumor to be transplanted was Lewis lung cancer. 2 ⁇ 10 6 Lewis lung cancer cells were implanted subcutaneously under the armpit of B 10 mice (male) to produce tumor-bearing mice.
- the dose of SM or AHCC was 1, OOmgmg / kg (0.1 ml / 10 g mouse body weight) per day, and it was administered orally every day for 20 days.
- IL-12 was measured in accordance with the product specifications using a Tota 1 Mouse Interface euk in-12 kit (Genzyme).
- the measurement of IAP was carried out using a mouse IAP plate (manufactured by Bacteriological Laboratories, Inc., sold by Sanko Junyaku Co., Ltd.) according to the product specifications.
- Tumor size (the major axis X minor 2/2 mm 3) was measured from day 1 of administration of SM after 1-9 days, was calculated tumor inhibition rate of the SM. Furthermore, the test-bearing mice continued to be bred for 20 days after SM administration, and the number of surviving days (life extension effect) was observed.
- the serum IL-12 level exceeds the normal level on the 7th day of the early stage of tumor-bearing, but on the 10th and 14th, the IL-12 level declines, reaching mid- and late-stage tumor-bearing It will be lower than normal on the 14th. It is an object of the invention to increase the IL-12 concentration below.
- AHCC reached its maximum production of IL-12 on the 7th day of administration, and the amount was almost the same as the value on the 10th day after the administration of the mycelium fraction of Shimane perennial fungus.
- IL-12 production ability decreased, and was only about 1.2 times that of untreated tumor-bearing mice.
- the mycelial fraction of Shimane perennial mushrooms has a lower initial (7th term) productivity than AHCC, but reaches a maximum on day 10 and then increases. The production capacity continued for a long time after the 14th day.
- the serum IAP concentration, an antitumor immunosuppressive protein exceeded the normal level already on the 7th day, the early stage of tumor-bearing, and on the 10th and 14th days, the middle and late stages of tumor-bearing. was significantly higher than the normal value. That is, as the cancer progresses, the concentration of IAP increases.
- the Shima perennial fungal mycelium fraction showed about 7% IAP inhibitory effect compared to untreated tumor-bearing mice, and on the 10th day, it showed a significant 60% inhibitory effect. Fruit. Further, on the 14th day of administration, an inhibitory effect of about 20% was exhibited, and the IAP inhibitory effect of the Shima perennial mushroom mycelium fraction continued for a long time.
- the effect of prolonging the survival days by administration of the mycelium fraction of Shima perennial mushrooms of the tumor-bearing mice was about 150% longer than that of the untreated tumor-bearing mice.
- the positive control AHCCC-treated mice did not show any survival benefit. It was also found that the mycelium fraction of Shimane perennial mushroom was superior to AHCC in terms of the survival rate of tumor-bearing mice.
- Tumor size (mm 3) major axis of tumor (mm) x tumor short diameter (mm) 2/2 Further, the suppression Seiritsu to the size of the tumor bearing mice by Shima million years mushroom mycelium fraction was calculated by the following equation.
- Tumor of SM-treated tumor-bearing mouse tumor-bearing + SM
- Tumor suppression rate 1-1 x 100 (%) Tumor of untreated tumor-bearing mouse [tumor-bearing (untreated)]
- Tumor suppression was not evident on day 7 of administration of the mycelium fraction of Shimane perennial fungus, but on day 10 of administration, the tumor inhibition rate showed a maximum value of 56.5%.
- the mycelium fraction of the mushroom mycelia showed a tumor suppression rate of 44.7% on the 14th day of administration and 29.3% on the 19th day of administration.
- the tumor of the mycelium fraction of Shimane perennial mushroom Table 3 Tumor size (mm 3 ) and tumor suppression rate (%)
- SM sample
- LLC Lewis Lun Carcinoma
- FIG. 2 shows the results obtained when ILX was used as a positive control sample having a known IL-12 production ability.
- SM is indicated as ILY.
- untreated tumor-bearing mice indicated by ⁇ in Fig. 2
- the serum IL-12 concentration was higher than the normal value in 7 at the early stage of tumor-bearing, but 10 and 14 were higher than IL. The concentration decreases and falls below normal levels on the 14th days, the middle and late stages of cancer.
- the time-dependent production of the antitumor cytokine IL-12 in the tumor-bearing mice was untreated on day 7 of administration. Although it was lower than that of cancer mice, on day 10 of administration, IL-12 production ability of the mycelium fraction of Shimane perennial mushroom was observed. As a result, IL-12 was significantly increased, and even on day 14 of administration. High productivity was maintained. Its production ability was about 1.7 times higher than that of the untreated tumor-bearing mouse, and the significance was observed on the 10th and 14th days after administration.
- ILX-administered tumor-bearing mice (indicated by ⁇ in Fig. 2) had the highest production of IL-12 on day 7 of administration, and their IL-12 production decreased on day 10 of administration. Although it was lower than that of ILY-administered tumor-bearing mice, production of IL-11 was observed even on day 14. In other words, Compared with ILX, the initial (day 7) productivity was low, but reached a maximum on day 10, and thereafter the high productivity continued for a long time after day 14. From this, it was confirmed that the Shima perennial fungal mycelium fraction can be expected to have the ability to induce IL-12 production characteristically in advanced stage terminal cancer. Clinical case
- PA PSA
- NITC new immunotherapy
- TNF, IFNy and IL-12 are well produced.
- the NC for the 12 months to June 26, 1999 was a slight increase.
- PA (PSA) and cancer Massemino protein increased.
- NITC will start on June 3, 2000. Since then, tumor titers increased for CEA, TPA, BCA225 and sialyl LEX-l (SLX-l).
- NITC NITC was launched on June 17, 1999.
- Various tumors were reduced and normalized with the exception of ICTP (PR).
- PR ICTP
- CEA was 5.6 ng / ml (5.0 or less)
- TPA was 120 U / ml (70 or less)
- ICTP also showed abnormal values and became PD.
- NITC NITC was launched on February 16, 1998.
- the tumor marker improved and was determined to be PR until August 7, 1999.
- the present invention provides a Shima perennial mushroom mycelium fraction that is effective for inducing IL-12 production, and furthermore, a cancer progression stage in the induction of IL-11 production in a Shima perennial mushroom mycelium fraction
- the effective administration time was determined.
- the composition according to the present invention, the composition for oral ingestion, the dietary supplement for oral ingestion, the commercial medium carrying the information on these, and the commercial method using the commercial medium are useful for the treatment of cancer. It can make a significant contribution in basic and clinical research, as well as in cancer treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Inks, Pencil-Leads, Or Crayons (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001568448A JPWO2001070251A1 (ja) | 2000-03-24 | 2001-03-23 | 抗がん組成物 |
EP01915717A EP1266661A1 (en) | 2000-03-24 | 2001-03-23 | Anticancer compositions |
AU2001242761A AU2001242761A1 (en) | 2000-03-24 | 2001-03-23 | Anticancer compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-128616 | 2000-03-24 | ||
JP2000128616 | 2000-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001070251A1 true WO2001070251A1 (fr) | 2001-09-27 |
Family
ID=18638029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/002315 WO2001070251A1 (fr) | 2000-03-24 | 2001-03-23 | Composition antineoplasique |
Country Status (5)
Country | Link |
---|---|
US (1) | US20030118606A1 (ja) |
EP (1) | EP1266661A1 (ja) |
JP (1) | JPWO2001070251A1 (ja) |
AU (1) | AU2001242761A1 (ja) |
WO (1) | WO2001070251A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003030938A1 (fr) * | 2001-10-09 | 2003-04-17 | Orient Cancer Therary Co.,Ltd. | Agents immunotherapeutiques contre le cancer |
JP2006254893A (ja) * | 2005-03-18 | 2006-09-28 | Takashi Miyake | 針葉樹さるのこしかけ培養液 |
JP2008255057A (ja) * | 2007-04-05 | 2008-10-23 | Noda Shokukin Kogyo Kk | 抗癌剤、抗癌剤の製造方法、及び飲食品 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5117166B1 (ja) * | 1973-12-27 | 1976-05-31 | ||
JPH0249732A (ja) * | 1988-08-12 | 1990-02-20 | Kureha Chem Ind Co Ltd | 抗催奇形性剤 |
EP0844002A1 (en) * | 1996-11-11 | 1998-05-27 | Akikuni Yagita | Use of activated hemicellulose for the induction of interleukin-12 |
JP2001106637A (ja) * | 1999-10-04 | 2001-04-17 | Amino Up Chemical Co Ltd | サイトカイン産生能評価方法、サイトカイン産生能回復剤組成物、その製造方法及び用途 |
-
2001
- 2001-03-23 EP EP01915717A patent/EP1266661A1/en not_active Withdrawn
- 2001-03-23 US US10/221,333 patent/US20030118606A1/en not_active Abandoned
- 2001-03-23 WO PCT/JP2001/002315 patent/WO2001070251A1/ja not_active Application Discontinuation
- 2001-03-23 JP JP2001568448A patent/JPWO2001070251A1/ja not_active Withdrawn
- 2001-03-23 AU AU2001242761A patent/AU2001242761A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5117166B1 (ja) * | 1973-12-27 | 1976-05-31 | ||
JPH0249732A (ja) * | 1988-08-12 | 1990-02-20 | Kureha Chem Ind Co Ltd | 抗催奇形性剤 |
EP0844002A1 (en) * | 1996-11-11 | 1998-05-27 | Akikuni Yagita | Use of activated hemicellulose for the induction of interleukin-12 |
JP2001106637A (ja) * | 1999-10-04 | 2001-04-17 | Amino Up Chemical Co Ltd | サイトカイン産生能評価方法、サイトカイン産生能回復剤組成物、その製造方法及び用途 |
Non-Patent Citations (2)
Title |
---|
BAE JI-HYUN: "Effects of ganoderma lucidum on the IL-1, TNF and IL-12 gene expression of macrophages", HAN'GUK SIKP'UM YONGYANG KWAHAK HOECHI, vol. 26, no. 5, 1997, pages 978 - 982, XP008034640 * |
IKUYA NAKAGAWA ET AL.: "Augmentation of cytolytic activity of mouse splenic cells by a heteroglycan-protein fraction from culture medium of ganoderma lucidum (rei-shi) mycelia", BIOTHERAPY, vol. 13, no. 5, 1999, pages 513 - 515, XP002944829 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003030938A1 (fr) * | 2001-10-09 | 2003-04-17 | Orient Cancer Therary Co.,Ltd. | Agents immunotherapeutiques contre le cancer |
JP2006254893A (ja) * | 2005-03-18 | 2006-09-28 | Takashi Miyake | 針葉樹さるのこしかけ培養液 |
JP2008255057A (ja) * | 2007-04-05 | 2008-10-23 | Noda Shokukin Kogyo Kk | 抗癌剤、抗癌剤の製造方法、及び飲食品 |
Also Published As
Publication number | Publication date |
---|---|
AU2001242761A1 (en) | 2001-10-03 |
EP1266661A1 (en) | 2002-12-18 |
EP1266661A9 (en) | 2003-03-05 |
JPWO2001070251A1 (ja) | 2004-06-10 |
US20030118606A1 (en) | 2003-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Guggenheim et al. | Immune modulation from five major mushrooms: application to integrative oncology | |
Gaullier et al. | Supplementation with a soluble beta-glucan exported from Shiitake medicinal mushroom, Lentinus edodes (Berk.) singer mycelium: a crossover, placebo-controlled study in healthy elderly | |
Namba | Maitake D-fraction: healing and preventive potential for cancer | |
KR101140753B1 (ko) | 악액질 치료에서 라노스테인 및 복령 추출물의 용도 | |
Guryanova et al. | Strategies for using muramyl peptides-modulators of innate immunity of bacterial origin-in medicine | |
DE69928093T2 (de) | Kombinationspräparat enthaltend monozyten-abgeleitete zellen zur behandlung von neoplastischen oder infektiösen erkrankungen | |
AU2011282200B2 (en) | Anti-viral properties of Aloe vera and Acquired Immune Deficiency Syndrome (AIDS) treatment | |
Chen et al. | The application of fungal beta-glucans for the treatment of colon cancer | |
EP1266940A1 (en) | Oil-base ink composition, writing utensils and dyes to be used therein | |
JP3621404B1 (ja) | 免疫力強化活性剤 | |
JPWO2003039568A1 (ja) | 抗癌組成物 | |
JPH10139670A (ja) | インターロイキン12誘導物質及び医薬組成物 | |
JP2003306442A (ja) | 抗酸化能と免疫賦活能とを有する製剤と製造方法 | |
WO2001070251A1 (fr) | Composition antineoplasique | |
WO2018209139A1 (en) | Nutraceutical blends | |
JPWO2003039567A1 (ja) | 抗癌組成物 | |
KR100506950B1 (ko) | 진세노사이드를 함유함을 특징으로 하는 면역증강효과에 대한 조성물 | |
US6818624B2 (en) | Therapeutic agent for a cancer and method of screening the same, and health-care auxillary food | |
JP2000159686A (ja) | シイタケ菌糸体抽出物由来のlak活性増強用製剤 | |
JPH02134325A (ja) | エイズ治療剤およびその製造方法 | |
JP2007204488A (ja) | 免疫賦活効果を相乗的に増強した製剤 | |
CN109198648A (zh) | 金虫癌症救星基酶肽 | |
JP4308350B2 (ja) | シイタケ菌糸体抽出物を含有するlak活性スクリーニング物質およびそれを用いたlak活性スクリーニング法 | |
WO2001054724A1 (fr) | Compositions anticancéreuses | |
WO2000032212A1 (fr) | Potentialisateur de l'activite lak obtenu a partir d'un extrait d'hypes du champignon shiitake, et preparations de potentialisation de l'activite lak contenant ledit potentialisateur |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 568448 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10221333 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001915717 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001915717 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001915717 Country of ref document: EP |